We were delighted to meet with Messoud Ashina (University of Copenhagen, Copenhagen, Denmark) to discuss his study results, investigating atogepant as a treatment option for migraine.
The abstract entitled: ‘Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- Could you tell us a little about atogepant and its potential advantages compared with current preventative treatment options for migraine? (0:14)
- What were the aims and design of the open label study? (2:43)
- What were the efficacy findings of the study and how do these compare with those reported in the ADVANCE study? (4:08)
Disclosures: Messoud Ashina has received personal fees from AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis and Teva; is the principal investigator for AbbVie/Allergan, Amgen, Eli Lilly and Lundbeck in ongoing clinical trials; has received Research grants form Lundbeck Foundation, Novo Nordisk Foundation, and Novartis; has no ownership interest and does not own stocks of any pharmaceutical company. Messoud Ashina is also an Associate Editor of Cephalalgia and associate editor of the Journal of Headache and Pain, and is the President of the International Headache Society.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
